卵巢成熟性囊性畸胎瘤恶性转化一例

doi:10.12280/gjfckx.20240004

摘要/Abstract

摘要：

卵巢成熟性囊性畸胎瘤（mature cystic teratoma of ovary，MCTO）是最常见的卵巢生殖细胞肿瘤，通常为良性，然而在极少数情况下，其可能发生恶性转化（malignant transformation，MT）。MT-MCTO多见于绝经后期女性，由于其罕见性，目前尚缺乏标准的诊治方案。报告1例77岁MT-MCTO为鳞状细胞癌ⅡB期患者的诊治过程，该患者在经肿瘤细胞减灭术后接受1个疗程博来霉素+依托泊苷+顺铂方案化疗。然而，由于患者身体情况无法耐受进一步治疗，随访术后半年死亡。

关键词: 畸胎瘤, 卵巢肿瘤, 癌, 鳞状细胞, 治疗, 预后

Abstract:

Mature cystic teratoma of ovary (MCTO) is the most common ovarian germ cell tumor, which is usually benign. However, in rare cases, it may undergo malignant transformation. Malignant transformation of MCTO (MT-MCTO) is common in postmenopausal women. Due to its rarity, there is still no standard diagnosis and therapeutic options. This paper reports the diagnosis and treatment of a 77-year-old patient with MT-MCTO to squamous cell carcinoma at stage ⅡB. After cytoreductive surgery, the patient received a course of chemotherapy with bleomycin+etoposide +cisplatin. However, because the patient's physical condition could not tolerate further treatment, the patient died after six months of postoperative follow-up.

Key words: Teratoma, Ovarian neoplasms, Carcinoma, squamous cell, Therapy, Prognosis

季安璇, 赵淑华. 卵巢成熟性囊性畸胎瘤恶性转化一例[J]. 国际妇产科学杂志, 2024, 51(4): 384-387.

JI An-xuan, ZHAO Shu-hua. Malignant Transformation of Mature Cystic Teratoma of Ovary: A Case Report[J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 384-387.

图/表 3

参考文献 20

[1]	Cong L, Wang S, Yeung SY, et al. Mature Cystic Teratoma: An Integrated Review[J]. Int J Mol Sci, 2023, 24(7):6141. doi: 10.3390/ijms24076141.
[2]	Hackethal A, Brueggmann D, Bohlmann MK, et al. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data[J]. Lancet Oncol, 2008, 9(12):1173-1180. doi: 10.1016/S1470-2045(08)70306-1. pmid: 19038764
[3]	Dadhich S, Manjunath SS, Swaminathan R. Malignant Transformation in a Mature Cystic Teratoma of the Ovary: An Unusual Case Presentation[J]. Cureus, 2023, 15(4):e37304. doi: 10.7759/cureus.37304.
[4]	Ziadeh H, Duforestel T, Bouredji K, et al. The evolution of mature cystic teratomas of the ovary into squamous cell carcinoma: two case reports and review of the literature[J]. J Obstet Gynaecol, 2022, 42(5):838-841. doi: 10.1080/01443615.2022.2035333.
[5]	Tamura R, Yoshihara K, Nakaoka H, et al. XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary[J]. Oncogene, 2020, 39(17):3541-3554. doi: 10.1038/s41388-020-1237-0. pmid: 32115573
[6]	Petljak M, Maciejowski J. Molecular origins of APOBEC-associated mutations in cancer[J]. DNA Repair (Amst), 2020,94:102905. doi: 10.1016/j.dnarep.2020.102905.
[7]	Tamura R, Nakaoka H, Yachida N, et al. Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma[J]. Cancer Sci, 2023, 114(5):2145-2157. doi: 10.1111/cas.15754.
[8]	Shi Z, Yang L, Bian C. Squamous cell carcinoma in mature cystic teratoma of the ovary induced by human papillomavirus 16 infection: A case report and literature review[J]. Medicine(Baltimore), 2022, 101(38):e30667. doi: 10.1097/MD.0000000000030667.
[9]	Chen H, Wang F, Hu X, et al. Preoperative clinical characteristics for differentiating malignant transformation from torsion of mature cystic teratoma[J]. J Obstet Gynaecol, 2023, 43(1):2151357. doi: 10.1080/01443615.2022.2151357.
[10]	Qin L, Zhao T, Liu X, et al. Malignant transformation arising from mature ovarian cystic teratoma: A case series[J]. Medicine(Baltimore), 2021, 100(13):e24726. doi: 10.1097/MD.0000000000024726.
[11]	Wang X, Li W, Kong Y, et al. Clinical analysis of 12 cases of ovarian cystic mature teratoma with malignant transformation into squamous cell carcinoma[J]. J Int Med Res, 2021, 49(2):300060520981549. doi: 10.1177/0300060520981549.
[12]	Mori Y, Nishii H, Takabe K, et al. Preoperative diagnosis of malignant transformation arising from mature cystic teratoma of the ovary[J]. Gynecol Oncol, 2003, 90(2):338-341. doi: 10.1016/s0090-8258(03)00259-2. pmid: 12893196
[13]	Li C, Zhang Q, Zhang S, et al. Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review[J]. BMC Cancer, 2019, 19(1):217. doi: 10.1186/s12885-019-5393-y. pmid: 30866852
[14]	Tehranian A, Ghahghaei-Nezamabadi A, Seifollahi A, et al. Ovarian mature cystic teratoma with malignant transformation: two case reports[J]. J Med Case Rep, 2021, 15(1):23. doi: 10.1186/s13256-020-02594-4.
[15]	Sibarani C, Permata HD, Martiana EF, et al. A rare case of squamous cell carcinoma transformation in a mature cystic teratoma of the ovary[J]. SAGE Open Med Case Rep, 2023,11:2050313X231193305. doi: 10.1177/2050313X231193305.
[16]	Fukase M, Ohta T, Watanabe N, et al. Squamous cell carcinoma arising from a mature cystic teratoma of the ovary: Successful treatment with carboplatin, paclitaxel, and bevacizumab[J]. Gynecol Oncol Rep, 2020,34:100632. doi: 10.1016/j.gore.2020.100632.
[17]	卢淮武, 叶栋栋, 吴斌, 等. 《2023 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(1):58-67. doi:10.19538/j.fk2023010116.
[18]	Wu M, Bennett JA, Reid P, et al. Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab[J]. Gynecol Oncol Rep, 2021,37:100837. doi: 10.1016/j.gore.2021.100837.
[19]	Li X, Tang X, Zhuo W. Malignant transformation of ovarian teratoma responded well to immunotherapy after failed chemotherapy: a case report[J]. Ann Palliat Med, 2021, 10(7):8499-8505. doi: 10.21037/apm-20-2429.
[20]	Song XC, Wang YX, Yu M, et al. Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor[J]. Front Oncol, 2022,12:789228. doi: 10.3389/fonc.2022.789228.